Nodular basal cell carcinoma is the most common subtype of basal cell carcinoma, which is itself the most common form of skin cancer. It appears as a shiny, dome-shaped bump that grows slowly over months or years, most often on sun-exposed areas like the face, ears, and neck. While it rarely spreads to other parts of the body, it can cause significant local damage to skin, cartilage, and bone if left untreated.
What It Looks Like
The classic sign is a pearly or translucent bump, meaning you can almost see through its surface. On lighter skin, the bump looks white or pink with a waxy sheen. On darker skin tones, it often appears brown or glossy black. In both cases, the bump typically has a rolled, raised border that gives it a slightly “built-up” edge compared to the surrounding skin.
Tiny blood vessels (called telangiectasias) are frequently visible on or near the surface, giving it a slightly reddish, spidery appearance. These vessels can be harder to spot on brown and Black skin. As the lesion grows, the center may flatten or break down into an ulcer that bleeds, crusts over, and then bleeds again. Some nodular BCCs also develop dark spots or a blue-grey coloring, which can make them look like a mole or melanoma at first glance.
Growth is slow but persistent. A small bump might sit unchanged for weeks, then gradually enlarge. Many people first notice it because it bleeds after minor contact, like toweling off after a shower, and the wound never fully heals.
What Causes It
Cumulative ultraviolet radiation exposure is the primary driver. Each significant sunburn and years of everyday sun exposure add up, damaging DNA in the basal cells that line the deepest layer of the outer skin. Fair skin, a history of sunburns, and living in high-UV environments all raise the risk substantially. Tanning bed use carries the same type of UV damage.
At the genetic level, nodular BCC is driven by disruption of a cell-growth signaling system called the Hedgehog pathway. Normally, a protein called PTCH1 acts as a brake on cell division. When UV damage causes loss-of-function mutations in the gene that produces PTCH1, or activating mutations in a partner protein called SMO, the brake releases and basal cells begin multiplying without the usual stop signals. Mutations in the tumor suppressor gene TP53 are also common in these cancers.
Immunosuppression is another significant risk factor. People who have received organ transplants and take anti-rejection medications develop basal cell carcinoma at much higher rates than the general population.
How It’s Diagnosed
Diagnosis starts with a visual exam, often aided by dermoscopy, a handheld magnifying tool with polarized light. Nodular BCC has a distinctive dermoscopic signature: branching (arborizing) blood vessels are present in roughly 75% of cases. Shiny white structures appear in about 43%, and ulceration in about 31%. Blue-grey oval nests and globules round out the pattern. When a dermatologist sees this constellation, nodular BCC is the leading suspect.
A biopsy confirms the diagnosis. Under a microscope, the tissue shows tight clusters of small, uniform cells with a characteristic fence-like arrangement (palisading) along the outer edge of each tumor nest, surrounded by a distinctive type of connective tissue. This microscopic appearance is what definitively separates nodular BCC from other subtypes and from other skin growths entirely.
Conditions That Can Look Similar
Several benign skin growths mimic nodular BCC at a glance. Sebaceous hyperplasia, a harmless overgrowth of oil glands, also produces small dome-shaped bumps on the face. The key difference is that sebaceous hyperplasia has a central dimple and uniform yellow lobules, while nodular BCC is pink or red and tends to grow over time. Blood vessel patterns also differ: vessels in sebaceous hyperplasia run neatly between the gland lobules, while those in BCC are scattered in a haphazard, branching pattern.
Other lookalikes include fibrous papules (firm, flesh-colored bumps on the nose), dermal nevi (common moles), and pyogenic granulomas (rapidly growing, reddish-purple vascular bumps often surrounded by a scaly collar). Any new or changing bump on sun-exposed skin that bleeds easily or doesn’t heal warrants evaluation.
Treatment Options
Surgery is the primary treatment. For well-defined nodular BCCs smaller than 2 centimeters, standard surgical excision with a 4-millimeter margin of healthy tissue around the visible tumor clears the cancer completely in more than 95% of cases. The procedure is typically done under local anesthesia in an office setting, and the wound is closed with stitches the same day.
For tumors in cosmetically sensitive or functionally important areas, like around the eyes, nose, lips, or ears, Mohs micrographic surgery is the preferred approach. In this technique, the surgeon removes thin layers of tissue one at a time, examining each under a microscope before going back for more. This spares the maximum amount of healthy skin while achieving cure rates up to 99% for new tumors and up to 94% for recurrent ones.
Nonsurgical options exist for specific situations. Superficial radiation therapy can be effective for patients who aren’t good candidates for surgery. Topical treatments and cryotherapy (freezing) are sometimes used for small, low-risk lesions, though they come with higher recurrence rates and no tissue sample to confirm the margins are clear. For rare advanced or metastatic cases, medications that block the Hedgehog signaling pathway can shrink tumors that can’t be managed surgically.
Prognosis and Recurrence
Nodular BCC has an excellent prognosis when caught and treated early. It is considered a low-risk subtype compared to more aggressive forms like infiltrative or morpheaform BCC. Metastasis is extremely rare for any basal cell carcinoma and even rarer for the nodular subtype specifically.
The real concern is local recurrence and new primary tumors. Having one BCC significantly raises the odds of developing another, either at the same site or elsewhere. Studies consistently show that people with a history of BCC develop new ones at rates far above the general population, especially within the first few years. This makes ongoing skin surveillance important: regular full-body skin checks, self-exams for new or changing bumps, and consistent sun protection all reduce the chance of another tumor going unnoticed.
Reducing Your Risk
Since UV exposure is the dominant modifiable risk factor, the most effective prevention strategies are straightforward. Daily broad-spectrum sunscreen on exposed skin, protective clothing, wide-brimmed hats, and avoiding peak sun hours between 10 a.m. and 4 p.m. all reduce cumulative UV damage. Avoiding tanning beds eliminates another high-intensity UV source entirely. For people with a history of BCC, these habits shift from general advice to a meaningful part of long-term care.